XERIS BIOPHARMA HOLDINGS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 79.03 million shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-03-11
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 121.94M shares, a 127.57% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 66.50M shares, a 44.11% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 53.58M shares.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 46.15M shares.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 79.03M shares, a 85.32% increase from fiscal 2020.
- XERIS BIOPHARMA HOLDINGS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 42.64M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | 121.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 94.22M shares derived: average of 2 quarters · filed 2022-03-11 | 79.03M shares 10-K · filed 2022-03-11 | |
| 2021-09-30 | 66.50M shares 10-Q · filed 2021-11-10 | 64.72M shares 10-Q · filed 2021-11-10 | ||
| 2020-12-31 | 53.58M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 49.86M shares derived: average of 2 quarters · filed 2022-03-11 | 42.64M shares 10-K · filed 2022-03-11 | |
| 2020-09-30 | 46.15M shares 10-Q · filed 2021-11-10 | 39.00M shares 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |